Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Efficacy and Safety of Combination Therapy with Tolvaptan and Furosemide in Children with Nephrotic Syndrome and Refractory Edema: A Prospective Interventional Study.

Authors:
Jitendra Meena Pankaj Hari Aditi Sinha Arvind Bagga

Indian J Pediatr 2022 Jan 26. Epub 2022 Jan 26.

Division of Nephrology, Department of Pediatrics, ICMR Center for Advanced Research in Nephrology, All India Institute of Medical Sciences, New Delhi, 110029, India.

Objective: Severe edema in children with nephrotic syndrome is often refractory to conventional diuretics. Tolvaptan has been used satisfactorily for managing edema in patients with heart failure and cirrhosis. The safety and efficacy of combination therapy with oral tolvaptan and intravenous (IV) furosemide was assessed in patients with furosemide refractory edema.

Methods: Patients, aged 5-18 y with nephrotic syndrome and severe edema, were screened for eligibility. After excluding hypovolemia, patients received IV furosemide (3-4 mg/kg/d) for 48 h. Those refractory to IV furosemide (weight loss < 3%) received tolvaptan (0.5-1 mg/kg once daily) and IV furosemide for the next 48 h. Parameters were compared between 48 h of furosemide alone and combination therapy.

Results: A total of 24 patients (18 boys) with mean age of 8.0 ± 3.0 y were enrolled. Urine volume significantly increased with combination therapy as compared to furosemide therapy (mean difference: 1.2 mL/kg/h; 95% CI: 0.8-1.65 mL/kg/h) (p < 0.001). Compared to therapy with furosemide alone, combination therapy resulted in significant reduction in body weight from 26.9 ± 10.3 kg to 24.8 ± 9.7 kg (p < 0.001). Estimated glomerular filtration rate did not change (p = 0.81) but serum sodium increased from 135.7 ± 3.3 mEq/L to 140.4 ± 4.8 mEq/L (p < 0.001) with combination therapy; 2 patients showed asymptomatic hypernatremia.

Conclusion: The combination of oral tolvaptan and IV furosemide is effective in augmenting diuresis and reducing weight in patients with furosemide refractory edema but requires monitoring of electrolytes and volume status.

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s12098-021-03988-yDOI Listing
January 2022

Publication Analysis

Top Keywords

nephrotic syndrome
12
syndrome refractory
8
severe edema
8
combination therapy
8
children nephrotic
8
furosemide
5
syndrome severe
4
heart failure
4
5-18 nephrotic
4
patients heart
4
patients
4
edema patients
4
failure cirrhosis
4
managing edema
4
satisfactorily managing
4
edema screened
4
tolvaptan satisfactorily
4
efficacy safety
4
weight loss 
4
aged 5-18
4

Keyword Occurance

Similar Publications

Multidisciplinary supportive care in systemic light chain amyloidosis.

Authors:
Bou Zerdan Maroun Sabine Allam Chakra P Chaulagain

Blood Res 2022 May 20. Epub 2022 May 20.

Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston FL, USA.

The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying plasma cell clone with or without high dose chemotherapy followed by autologous stem cell transplantation using melphalan based conditioning. Now with the approval of highly tolerable anti-CD38 monoclonal antibody daratumumab based anti-plasma cell therapy in 2021, high rates of hematologic complete responses are possible even in patients who are otherwise deemed not a candidate for autologous stem cell transplantation. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.

Authors:
Paolo Menè Antonella Stoppacciaro Silvia Lai Francescaromana Festuccia

Int J Nephrol Renovasc Dis 2022 13;15:173-183. Epub 2022 May 13.

Division of Nephrology, Department of Internal Medicine, Sant'Andrea University Hospital, Rome, Italy.

"Cast nephropathy" (CN) is a pathological feature of myeloma kidney, also seen to a lesser extent in the context of severe nephrotic syndrome from non-haematological diseases. The name relates to obstruction of distal tubules by "casts" of luminal proteins concentrated by intensive water reabsorption resulting from dehydration or high-dose diuretics. Filtered proteins form complexes with endogenous tubular Tamm-Horsfall glycoprotein. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Clinical and histopathological features related to time to complete remission in adult-onset minimal change nephrotic syndrome patients with corticosteroid treatment.

Authors:
Fumiyuki Morioka Shinya Nakatani Kozo Nishide Yuri Machiba Hideki Uedono Akihiro Tsuda Eiji Ishimura Katsuhito Mori Masanori Emoto

Clin Exp Nephrol 2022 May 19. Epub 2022 May 19.

Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Background: Minimal change nephrotic syndrome (MCNS) is a common type of nephrotic syndrome in adults, though evidence regarding its clinical and histopathological features related to time to complete remission (CR) is limited.

Methods: This was a retrospective study of biopsy-proven, first-onset, adult MCNS patients who achieved CR after undergoing corticosteroid treatment. Body weight (BW) change rate was calculated as follows: (BW at admission - BW at discharge)/BW at discharge × 100. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Focal segmental glomerulosclerosis: Risk for recurrence and interventions to optimize outcomes following recurrence.

Authors:
Lyndsay A Harshman Sharon Bartosh Rachel M Engen

Pediatr Transplant 2022 May 19:e14307. Epub 2022 May 19.

University of Wisconsin Madison, Madison, Wisconsin, USA.

Background: FSGS is a common indication for kidney transplant with a high-risk of posttransplant recurrence.

Methods: In this review, we summarize current knowledge about FSGS recurrence after kidney transplantation, including epidemiology, pretransplant planning, posttransplant management, and investigational treatments.

Results: FSGS recurs in 14%-60% of first transplants, likely associated with a circulating permeability factor. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

A Case of Minimal Change Disease after SARS-CoV-2 Vaccination under the Age of 18.

Authors:
Mohamad Nour Alhosaini

Avicenna J Med 2022 Jan 10;12(1):31-33. Epub 2022 Mar 10.

Department of Nephrology, American Hospital, Dubai, United Arab Emirates.

This is a care report of a 16-year-old-male who developed de novo minimal change disease following the second dose of the Pfizer vaccine. The patient developed sudden onset edema and 10 kg weight gain. He had nephrotic range proteinuria with normal renal function. Read More

View Article and Full-Text PDF
January 2022
Similar Publications
}